Last reviewed · How we verify
NCT06096935: CHARCOTEX
Exome Evaluation in Patients Living with Diabetes Complicated by Charcot Neuroarthropathy.
trial testing bood sample in Type 2 Diabetes in 40 participants. Completed in 18 January 2025.
18 January 2025
Quick facts
| Lead sponsor | Centre Hospitalier Sud Francilien |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 11 July 2024 |
| Primary completion | 18 January 2025 |
| Estimated completion | 18 January 2025 |
| Sites | 1 location across France |
Drugs / interventions tested
- bood sample
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
Centre Hospitalier Sud Francilien
Who can join
Adults 18 to 70, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Diabetes, like obesity, has reached worldwide proportions such that we're talking about a pandemic. These two diseases are a major cause of mortality and multiple complications. The medical and financial stakes involved make these two diseases a major public health issue. Two groups of factors contribute to these diseases: the environment and genetics. The use of next-generation sequencing (NGS) is a highly relevant tool for identifying mutations in already known genes, or new genes involved in the disease, for diagnostic purposes. This approach makes it possible to validate previously described genes and/or discover new loci linked to new signalling pathways involved in the pathophysiology of Charcot's foot in patients with diabetes
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06096935
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Centre Hospitalier Sud Francilien trials
Trials by the same sponsor.
- NCT07495709 — Reactions to Oro-facial Solicitations : a Predictor of Eating Difficulties for Premature Babies of 36 Weeks Gestation Ad · not yet recruiting
- NCT07430293 — Hybrid Closed-Loop Insulin Delivery After Pancreatectomy · NA · not yet recruiting
- NCT07414186 — Study of Pre Hospital Management of Polytrauma Patients by Medical Teams From a Department in the Parisian Region · not yet recruiting
- NCT07144059 — Impact of Non-medicalized ECG Practices Initiated by SAMU in Dispatch Strategies · not yet recruiting
- NCT07329192 — Study on How Parents' Anticipated Choice of a Doctor at the Maternity Hospital Influences the Newborn's First Post-disch · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06096935 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Sud Francilien
- Last refreshed: 14 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06096935.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing